Recon: FDA expands use of remdesivir for COVID-19; Nestle to buy Aimmune for $2B

• FDA head says he is willing to fast-track Covid-19 vaccine (FT) (Reuters) (The Hill)
• FDA expands emergency use of Gilead's remdesivir in hospitalized COVID-19 patients (Reuters) (FDA)
• GSK, partner Vir join race to find COVID-19 antibody treatment (Reuters) (STAT)
• US scraps Philips ventilator order in 2020 earnings blow (Reuters)
• US government’s Darpa probes Moderna’s vaccine patents (FT)
• Moderna failed to disclose federal funding for vaccine patent applications, advocates say (STAT)
• US Will Revive Global Virus-Hunting Effort Ended Last Year (NYTimes)
• GoodRx files to go public with a rare characteristic: Profits (CNBC) (Endpoints)
• Inside Trump’s pressure campaign on federal scientists over a covid-19 treatment (Washington Post)

• Nestle pays $2 billion to secure Aimmune's allergy treatment (Reuters) (Financial Times) (Endpoints)
• Chinese Covid-19 Vaccine Maker in Talks With Countries on Early Approval (WSJ)
• Scientists see downsides to top COVID-19 vaccines from Russia, China (Reuters)
• Explainer: How common cold viruses are being used in vaccines from Russia, China (Reuters)
• EU offers 400 million euros to WHO-led COVID-19 vaccine initiative (Reuters)
• Canada to purchase 76 million doses of Novavax coronavirus vaccine, company says (CNBC)
• Germany eyes global health ambitions as US steps back (Politico)
• COVID-19 can wipe out health care progress in short order: WHO (Reuters)
• Daiichi Sankyo's COVID-19 vaccine selected by Japanese drug discovery body (Reuters)
• More than 2,000 Australians a year dying from drug overdoses (The Guardian)

• Industry group says FDA botched COVID-19 convalescent plasma guidance (PharmaPhorum)
• Poll: Most Americans believe the Covid-19 vaccine approval process is driven by politics, not science (STAT)
• Here’s how the US could release a COVID-19 vaccine before the election—and why that scares some (Science)
• Abbott is testing its rapid coronavirus test on asymptomatic people in hopes of expanding FDA authorization (CNBC)
• European Leaders Weigh New Lockdowns as Cases Rise (NYTimes)
• Coronavirus Notebook: UK Reveals Plans For Pre-Approval Use Of COVID-19 Vaccine (Pink Sheet)

• Roche to Close Puerto Rico Plant After More Than Four Decades (Bloomberg)
• With latest data, a gene therapy for a deadly brain disease inches closer to market (BioPharmaDive)
• BioMarin's hemophilia gene therapy could have warranted a record price tag, ICER finds (BioPharmaDive)
• Nearly a year since opening its doors, here’s how Verily’s addiction medicine campus is taking shape (STAT)
• Ionis strikes deal to buy back lipid disease spinout Akcea (Fierce) (Endpoints)
• ESC: Merck's Steglatro shows limited promise with heart failure hospitalization data (Fierce)
• ESC: Novartis' Entresto racks up a heart failure study win—but it's a mixed one (Fierce)
• ESC: AstraZeneca's Farxiga cuts kidney disease risks by 39% in trial that could 'rewrite' the treatment textbook (Fierce)
• ESC: Amgen chases pediatric use for cholesterol-busting PCSK9 med Repatha (Fierce)
• ESC: Pfizer, BMS' Eliquis tops Xarelto, vitamin K drugs for site-specific bleeding risks in French real-world study (Fierce)
• ESC: Eli Lilly, Boehringer's Jardiance slices CV events by 25% in Farxiga-matching heart failure trial (Fierce)
• ESC: Amarin's Vascepa reduces patients' arterial plaque after 18 months of treatment (Fierce)
• ESC: MyoKardia's mavacamten boosts heart function in phase 3, teeing up 2021 filing (Fierce)
• Romark snares FDA nod to make diarrhea med Alinia at Puerto Rico plant—and supply a COVID-19 candidate's trials, too (Fierce)
• Gene therapy upstart recruits more ex-AveXis talent; I-Mab reveals first-half results (Endpoints)
• Novartis says its Soliris add-on might be able to replace the Alexion drug altogether. But is it too late? (Endpoints)
• Sold for pennies, Unum gets one last shot at redemption (Endpoints)
• How EFPIA Set The Bar On Drug Safety Reporting During COVID-19 (Pink Sheet)
• China Regulatory Express: Former CFDA Commissioner Bi Makes Comeback (Pink Sheet)
• Kymera Debuts On The Public Markets (LifeSciVC)

• Stryker again extends tender offer for Wright Medical shares (MedtechDive)
• Quality Problems With Medical Gowns Leads To FDA Warning (MedtechInsight)
• Philips pens $275M Intact Vascular deal to acquire implant (MedtechDive)
• FAQ Sheet From HHS Says FDA ‘Rarely Enforced’ Premarket Review Of LDTs (MedtechInsight)
• Tandem's artificial pancreas shows real-world blood sugar control in young children with Type 1 diabetes (Fierce)
• Elon Musk’s Neuralink unveils prototype of brain implants — and looks toward clinical trials (STAT)
• Baxter Announces FDA De Novo Authorization for Theranova Dialyzers Enabling HDx Therapy (Press)

• First PREP Act Immunity Decision That We’ve Seen (Drug & Device Law)
• Theranos Ex-COO Wants Latest Indictments Dismissed (Law360)
• Hologic Gets NovaSure Patent Judgment Bumped Up To $7M (Law360)
• Baxalta Inc. v. Genentech, Inc. (Fed. Cir. 2020) (Patent Docs)